| Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development. | |
| | |
MedLine Citation:
|
PMID: 17395088 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Drug development attrition rates are rising and late phase attrition remains high, contributing to an unsustainable increase in R&D spending. Consequently, there is much effort to identify the potentially successful molecules earlier in development with the use of biomarkers to predict potential efficacy and safety. However, focussing only on picking the winners earlier will not solve the problem. It is essential that the evaluation of these biomarkers also enables the earlier termination of the molecules that will not have the required activity. |
| | |
Authors:
|
Richard W Peck |
Related Documents
:
|
17276568 - The political economy of aids leadership in developing countries: an exploratory analysis. 15829368 - The use of forests for the purpose of tourism: the case of belek tourism center in turkey. 8300028 - Drugs and aids in southeast-asia. 21761788 - Delivering oxygen therapy in acute care: part 2. 9240128 - Functional problems in adult rectal prolapse and controversies in surgical treatment. 15216818 - China: people living with hiv complain about conduct of medical research. |
Publication Detail:
|
Type: Journal Article; Review Date: 2007-02-20 |
Journal Detail:
|
Title: Drug discovery today Volume: 12 ISSN: 1359-6446 ISO Abbreviation: Drug Discov. Today Publication Date: 2007 Apr |
Date Detail:
|
Created Date: 2007-03-30 Completed Date: 2007-07-05 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9604391 Medline TA: Drug Discov Today Country: England |
Other Details:
|
Languages: eng Pagination: 289-94 Citation Subset: IM |
Affiliation:
|
Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK. peck_richard_w@lilly.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biological Markers
/
analysis* Clinical Trials as Topic / methods*, trends Drug Design* Drug Industry / economics, methods, trends Humans Models, Theoretical Research / economics, methods, trends |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Physiological, pathological and potential therapeutic roles of ghrelin.
Next Document: Computational systems biology in drug discovery and development: methods and applications.